- $5.7m Milestone Monetization Agreement with AOP
- Results of 2024 Annual General Meeting
- New Drug Application for Accrufer® in South Korea
- Audited results for the year ended 31 Dec 2023
- Business Update for Q1 2024
- Notice of Results
- Unaudited Full Year Trading Update
- Appointment of new Chief Financial Officer
- Q3 2023 U.S. Commercial Highlights
- PDMR Transaction Notification
More ▼
Key statistics
On Monday, Shield Therapeutics PLC (STX:LSE) closed at 1.60, 50.59% above the 52 week low of 1.06 set on Apr 25, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 1.60 |
---|---|
High | 1.65 |
Low | 1.65 |
Bid | 1.50 |
Offer | 1.80 |
Previous close | 1.60 |
Average volume | 1.02m |
---|---|
Shares outstanding | 782.06m |
Free float | 293.18m |
P/E (TTM) | -- |
Market cap | 12.51m GBP |
EPS (TTM) | -0.0458 GBP |
Data delayed at least 20 minutes, as of Jul 22 2024 16:20 BST.
More ▼
Investors Chronicle View
The last IC recommendation on Shield Therapeutics PLC shares was Hold at 155.00 on 08 Aug 2019Read the full article